Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others), By Method (Centrifugation, Depth Filtration, Chromatography, and Others), By Application (Neurology, Hematology, Oncology, Immunology, and Others), By End User (Hospitals & Clinics, Academic & Research Institutes, and Others), By Region, and Competition

The Global Plasma Fractionation Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing prevalence of chronic diseases among all age groups such as immunological disorders graves diseases along with increasing demand for immunoglobulins for the treatment of chronic diseases.

Additionally, growing prevalence of blood and respiratory disorders due to and growing advancement in technology to cure the diseases has significantly increased the demand for plasma fractionation across different parts of the globe. Additionally, growing geriatric population across the globe which is susceptible to different kinds of chronic diseases is further expected to increase the demand for plasma fractionation, thereby fuelling the market growth through 2028. Besides, growing awareness about the advantages of using plasma fractions for the diagnosis of chronic diseases across the globe is further expected to support the plasma fractionation market during the forecast period. Furthermore, increasing research and development activities related to immunoglobulin is further expected to increase the demand for dental contouring. According to the Statista, as of 2022, around 51 percent of patients with Bernard Soulier syndrome were female, while to 49 percent were male. Plasma is the raw material used in plasma fractionation, and its availability is limited by regulations, donor eligibility criteria, and the cost of collection and processing. The shortage of plasma can lead to higher prices of plasma-derived therapies, which can limit their availability and affordability. The plasma fractionation market is subject to strict regulations from government agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations can be complex and time-consuming, and can lead to delays in the approval of new plasma-derived therapies.

Plasma-derived therapies are often more expensive than other types of therapies, due to the complex and costly process of plasma fractionation. This can limit their availability and affordability, particularly in low- and middle-income countries. Biosimilars are cheaper versions of biologic drugs that are similar in quality, safety, and efficacy. The increasing availability of biosimilars in the plasma fractionation market can lead to competition and price pressure for plasma-derived therapies. The increasing demand for Ig products is due to their efficacy in treating a wide range of diseases and their ability to provide long-lasting protection. The process of plasma fractionation begins with the collection of plasma from donors. Plasma is the liquid portion of blood that contains proteins, such as albumin, immunoglobulins, and clotting factors, as well as electrolytes, hormones, and other nutrients. The collected plasma is then transported to a plasma fractionation facility where it undergoes a series of processing steps to separate its various components. One of the primary products of plasma fractionation is immunoglobulin therapy. Immunoglobulins, also known as antibodies, are proteins that play a critical role in the immune system's response to infections. Immunoglobulin therapy involves the infusion of concentrated immunoglobulin products into patients with immunodeficiencies, such as primary immunodeficiency, chronic lymphocytic leukemia, and multiple myeloma, to help boost their immune function. While plasma fractionation has revolutionized the treatment of many medical conditions, it is not without its challenges. One of the biggest challenges facing the plasma fractionation industry is the shortage of plasma donors. Plasma donation is a time-consuming process that requires donors to undergo a thorough screening process and spend several hours hooked up to a plasma collection machine. As a result, the demand for plasma-derived therapies often exceeds the supply of raw materials, leading to shortages and increased prices.

Growing Prevalence of Immunodeficiency disorder

Increasing incidence of blood and immune disorders, off label usage of critical plasma products like albumins, immunoglobulins is the main factors which will boost the market growth during the forecast period. Similarly, rising use of immunoglobulins and alpha-1-antitrypsin in the medical sectors as a plasma fraction will propel the growth of the market. Similarly, increasing demand for plasma related therapies is important for the treatment of new diseases. In the present years, usage of protease inhibitors like alpha-1-antitrypsin protein is increased for the treatment of lung diseases and hepatic diseases, this in turn is expected create a lucrative growth for the market in the forecast period. For instance, according to the March 2021 report of the Alzheimer’s Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer’s-related dementia in the United States. Several companies have invested in increasing their plasma collection capacity in response to the growing demand for plasma-derived therapies. This has helped to address the shortage of raw materials for plasma fractionation and improve the availability of these therapies. The prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is increasing worldwide. This has led to an increase in the demand for plasma-derived therapies, which are used to treat these diseases. The global population is aging, and this has led to an increase in the prevalence of age-related diseases, such as Alzheimer's and Parkinson's disease. Plasma-derived therapies are used to treat these diseases, and this has contributed to the growth of the plasma fractionation market. Immunoglobulin products are used to treat a wide range of diseases and conditions, including immune deficiencies, autoimmune diseases, and neurological disorders. The increasing demand for these products is due to their efficacy in treating these conditions, and their ability to provide long-lasting protection.

Development of New Technologies

Major players are investing in different therapies that will produce reliable results. Manufactures are focusing on new therapies such as IgA, Plasmin and Ceruloplasmin. This, in turn, is expected to create a lucrative growth in the forecast period. A rapid chang in healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in the developing countries like North America. In 2019, there were around 195,263 people worldwide who had been diagnosed with hemophilia and 80,302 who had been diagnosed with von Willebrand disease. Several new plasma-derived therapies have been developed in recent years, including drugs for the treatment of rare diseases, such as alpha-1 antitrypsin deficiency and hereditary angioedema. These therapies have the potential to provide significant benefits to patients with these conditions. There have been several advancements in plasma fractionation technology, including the use of novel chromatography and virus inactivation methods. These advancements have improved the efficiency and safety of the plasma fractionation process, leading to increased production of plasma-derived therapies. Several companies have entered into collaborations and partnerships to expand their capabilities and reach in the plasma fractionation market. For example, in 2021, Takeda Pharmaceutical Company and CSL Behring announced a partnership to co-develop and co-commercialize a plasma-derived therapy for the treatment of severe respiratory disease.

Recent Development

• For instance, in March 2021, according to the WHO Model List of essential medicines includes several plasma-derived medicinal products (PDMPs), identifying them as drugs thought to be the most efficient and secure for addressing the most essential requirements in a health system and provide the best guidelines on increased supply of PDMPs in low & middle-income countries
• For instance, in April 2020, to create a viable plasma-derived medication for treating COVID-19, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma.
• For instance, in April 2019, under a long-term initiative to support people with hemophilia, Grifols International SA, a supplier of plasma-derived therapeutics, provided blood clotting factor medications (100 million international units) for the treatment of hemophilic patients.
• Idelvion by CSL Behring: Idelvion is an extended half-life factor IX product for the treatment of hemophilia B that was launched in 2018. It is produced using CSL Behring's plasma fractionation technology and is designed to provide longer-lasting protection against bleeding episodes.
• ALPROLIX and ELOCTATE by Sanofi: These are two extended half-life factor VIII products for the treatment of hemophilia A that were launched in 2019. They are produced using Sanofi's proprietary plasma fractionation technology and are designed to provide longer-lasting protection against bleeding episodes.
• CUVITRU by Takeda: CUVITRU is a subcutaneous immunoglobulin therapy for the treatment of primary immunodeficiency that was launched in 2018. It is produced using Takeda's plasma fractionation technology and is designed to be administered at home by patients or their caregivers.
• Hizentra by CSL Behring: Hizentra is a subcutaneous immunoglobulin therapy for the treatment of primary immunodeficiency that was launched in 2019. It is produced using CSL Behring's plasma fractionation technology and is designed to provide convenient and flexible dosing options for patients.
• HyperRAB S/D by Grifols: HyperRAB S/D is a rabies immune globulin therapy that was launched in 2020. It is produced using Grifols' plasma fractionation technology and is designed to provide rapid and effective protection against rabies infection.

Download Free Sample Report

Market Segmentation

The global plasma fractionation market can be segmented by product, method, application, end user and by region. Based on product, the market can be segmented into Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others. Based on method, the market can be differentiated into Centrifugation, Depth Filtration, Chromatography, and Others. Based on application, the market can be grouped into Neurology, Hematology, Oncology, Immunology, and Others. Based on end user, the market can be segmented into Hospitals & Clinics, Academic & Research Institutes, Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global plasma fractionation market on account of the growing demand for new therapies for the treatment of chronic diseases in the country.

Market Players

Grifols S.A., Octapharma AG, Intas Pharmaceuticals Ltd, LFB S.A., Takeda Pharmaceutical Company Limited, CSL Limited, Biotest AG, Kedrion S.p.A, Bio Products Laboratory Ltd.’, Bharat Serums and Vaccines Limited are some of the leading players operating in the Global Plasma Fractionation Market.

Report Scope:

In this report, global plasma fractionation market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Plasma Fractionation Market, By Product:

o    Albumin

o    Immunoglobulins

o    Coagulation Factors

o    Protease Inhibitors

o    Others

• Plasma Fractionation Market, By Method:

o    Centrifugation

o    Depth Filtration

o    Chromatography

o    Others

• Plasma Fractionation Market, By Application:

o    Neurology

o    Hematology

o    Oncology

o    Immunology

o    Others

• Plasma Fractionation Market, By End User:

o    Hospitals & Clinics

o    Academic & Research Institutes

o    Others

• Plasma Fractionation Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Turkey
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Plasma Fractionation Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Plasma Fractionation Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]